CA2559634A1 - Pharmaceutical preparations for the treatment of arthritis - Google Patents
Pharmaceutical preparations for the treatment of arthritis Download PDFInfo
- Publication number
- CA2559634A1 CA2559634A1 CA002559634A CA2559634A CA2559634A1 CA 2559634 A1 CA2559634 A1 CA 2559634A1 CA 002559634 A CA002559634 A CA 002559634A CA 2559634 A CA2559634 A CA 2559634A CA 2559634 A1 CA2559634 A1 CA 2559634A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- composition according
- glucosamine
- selenium
- manganese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010003246 arthritis Diseases 0.000 title claims abstract description 11
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 51
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 22
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 13
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract description 13
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000010949 copper Substances 0.000 claims abstract description 13
- 229910052802 copper Inorganic materials 0.000 claims abstract description 13
- 239000011572 manganese Substances 0.000 claims abstract description 13
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 13
- 239000011669 selenium Substances 0.000 claims abstract description 13
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 13
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 12
- 239000011707 mineral Substances 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 11
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 11
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 11
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 11
- 102000008186 Collagen Human genes 0.000 claims abstract description 10
- 108010035532 Collagen Proteins 0.000 claims abstract description 10
- 229920001436 collagen Polymers 0.000 claims abstract description 10
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 9
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960002442 glucosamine Drugs 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 10
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical group OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 7
- 240000007551 Boswellia serrata Species 0.000 claims description 6
- 244000192528 Chrysanthemum parthenium Species 0.000 claims description 6
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 6
- 235000008384 feverfew Nutrition 0.000 claims description 6
- 235000018062 Boswellia Nutrition 0.000 claims description 5
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 5
- 244000082490 Proboscidea louisianica Species 0.000 claims description 5
- 235000015926 Proboscidea louisianica ssp. fragrans Nutrition 0.000 claims description 5
- 235000015925 Proboscidea louisianica subsp. louisianica Nutrition 0.000 claims description 5
- 235000019096 Proboscidea parviflora Nutrition 0.000 claims description 5
- 240000002493 Smilax officinalis Species 0.000 claims description 5
- 235000008981 Smilax officinalis Nutrition 0.000 claims description 5
- 229940096399 yucca root Drugs 0.000 claims description 5
- 108010004032 Bromelains Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 235000019835 bromelain Nutrition 0.000 claims description 4
- 150000002301 glucosamine derivatives Chemical class 0.000 claims description 3
- 102000000503 Collagen Type II Human genes 0.000 claims description 2
- 108010041390 Collagen Type II Proteins 0.000 claims description 2
- 244000299452 Gouania lupuloides Species 0.000 claims 1
- 235000000292 Gouania lupuloides Nutrition 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 description 9
- 210000000845 cartilage Anatomy 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 241001278097 Salix alba Species 0.000 description 2
- 241000899950 Salix glauca Species 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- 241000254191 Harpagophytum procumbens Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YTWQDQXQXNAHQJ-UHFFFAOYSA-N Salacin Natural products CCC(=O)CCC1N(C=O)CCC11C2=CC=CC=C2NC1=O YTWQDQXQXNAHQJ-UHFFFAOYSA-N 0.000 description 1
- 241000362909 Smilax <beetle> Species 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 235000004584 Yucca mohavensis Nutrition 0.000 description 1
- 244000110633 Yucca schidigera Species 0.000 description 1
- 235000006012 Yucca schidigera Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The pharmaceutical composition for treating arthritis comprises glucosamine or a salt thereof, plant materials or extracts, collagen, pantothenic acid and minerals. The minerals may be copper, manganese and selenium. The composition is made in a form for oral administration.
The combination of the mineral components with the glucosamine and the plant materials produces a synergistic action in treating arthritis.
The combination of the mineral components with the glucosamine and the plant materials produces a synergistic action in treating arthritis.
Description
PHARMACEUTICAL PREPARATIONS
FOR THE TREATMENT OF ARTHRITIS
Field of the Invention The invention pertains to compositions for treating arthritis in humans and animals.
Background of the Invention Medications for oral administration are known for the treatment of arthritis which contain glucosamine, protein and various herbal materials or extracts. It has been discovered by the present inventors that the addition of certain compositions including minerals to such medications can produce a medication having an enhanced effectiveness in treating arthritis, and in particular in helping to form connective tissue in the afflicted joints and to prevent further cartilage deterioration.
Summary of the Invention The invention provides a pharmaceutical composition for treating arthritis comprising glucosamine or a salt thereof, plant materials or extracts, collagen, pantothenic acid, and minerals. The glucosamine salt is preferably glucosamine sulphate. The minerals are preferably copper, manganese and selenium. The composition can be made in a form for oral administration, such as a capsule, and each capsule preferably contains at least 375 mg of glucosamine sulphate, 5 mg of pantothenic acid, 350 mg of copper, 750 mg of manganese and 13 mcg (micrograms) of selenium, in addition to the other components. The combination in the composition of the mineral components with the glucosamine and the plant materials produces a synergistic action in treating the arthritis and the pain caused by it.
FOR THE TREATMENT OF ARTHRITIS
Field of the Invention The invention pertains to compositions for treating arthritis in humans and animals.
Background of the Invention Medications for oral administration are known for the treatment of arthritis which contain glucosamine, protein and various herbal materials or extracts. It has been discovered by the present inventors that the addition of certain compositions including minerals to such medications can produce a medication having an enhanced effectiveness in treating arthritis, and in particular in helping to form connective tissue in the afflicted joints and to prevent further cartilage deterioration.
Summary of the Invention The invention provides a pharmaceutical composition for treating arthritis comprising glucosamine or a salt thereof, plant materials or extracts, collagen, pantothenic acid, and minerals. The glucosamine salt is preferably glucosamine sulphate. The minerals are preferably copper, manganese and selenium. The composition can be made in a form for oral administration, such as a capsule, and each capsule preferably contains at least 375 mg of glucosamine sulphate, 5 mg of pantothenic acid, 350 mg of copper, 750 mg of manganese and 13 mcg (micrograms) of selenium, in addition to the other components. The combination in the composition of the mineral components with the glucosamine and the plant materials produces a synergistic action in treating the arthritis and the pain caused by it.
These and other features of the invention will be apparent from the following description of the preferred embodiments.
Description of the Preferred Embodiments The pharmaceutical compositions of the invention are for oral administration and comprise components which serve a number of necessary functions in effectively treating arthritis. These functions include relieving pain, relieving inflamation, rebuilding cartilage and preventing cartilage deterioration. The compositions comprise glucosamine or a salt thereof, plant materials, collagen, pantothenic acid (Vitamin B5), and minerals, preferably copper, manganese and selenium.
Glucosamine is an amino acid derivative. It is used in the composition to protect against deterioration of cartilage and contribute to the building of heathy cartilage. It is preferably in the form of one of its salts, such as glucosamine sulphate (which is preferred) or glucosamine hydrochloride. One dose of the composition contains approximately 375 mg of glucosamine sulphate, or the equivalent amount of glucosamine in another form.
The plant materials or extracts that are components of the composition are preferably boswellia extract, white willow bark, yucca root powder, devil's claw, sarsaparilla, feverfew leaf powder and bromelain.
Boswellia extract acts as an anti-inflammatory agent. The preferred form used in the composition is derived from Boswellia serrata and is standardized to contain about 65% boswellic acid. One dosage of the composition contains approximately 10 mg of boswellia extract.
Description of the Preferred Embodiments The pharmaceutical compositions of the invention are for oral administration and comprise components which serve a number of necessary functions in effectively treating arthritis. These functions include relieving pain, relieving inflamation, rebuilding cartilage and preventing cartilage deterioration. The compositions comprise glucosamine or a salt thereof, plant materials, collagen, pantothenic acid (Vitamin B5), and minerals, preferably copper, manganese and selenium.
Glucosamine is an amino acid derivative. It is used in the composition to protect against deterioration of cartilage and contribute to the building of heathy cartilage. It is preferably in the form of one of its salts, such as glucosamine sulphate (which is preferred) or glucosamine hydrochloride. One dose of the composition contains approximately 375 mg of glucosamine sulphate, or the equivalent amount of glucosamine in another form.
The plant materials or extracts that are components of the composition are preferably boswellia extract, white willow bark, yucca root powder, devil's claw, sarsaparilla, feverfew leaf powder and bromelain.
Boswellia extract acts as an anti-inflammatory agent. The preferred form used in the composition is derived from Boswellia serrata and is standardized to contain about 65% boswellic acid. One dosage of the composition contains approximately 10 mg of boswellia extract.
White willow bark acts as a pain reliever in the composition. It is preferably prepared from Salalix alba in a form standardized to 25%
salacin. One dosage of the composition contains approximately 50 mg of white willow bark.
Yucca root powder acts as an anti-inflammatory agent in the composition. It is derived from Yucca schidigera. One dosage of the composition contains approximately 15 mg of yucca root powder.
Devil's claw acts as an anti-inflammatory agent in the composition.
It is derived from Harpagophytum procumbens. One dosage of the composition contains approximately 15 mg of devil's claw.
Sarsaparilla acts as an anti-inflammatory agent in the composition.
It is derived from Smilax sp. One dosage of the composition contains approximately 15 mg of sarsaparilla.
Feverfew leaf powder acts as a pain reliever in the composition. It is derived from Tanacetum parthenium. One dosage of the composition contains approximately 10 mg of feverfew leaf powder.
Bromelain acts as an anti-inflammatory agent in the composition.
One dosage of the composition contains approximately 5 mg.
The collagen used in the composition is preferably Type II collagen.
The unhydrolyzed form is preferred for ready absorption into the body tissues. Collagen promotes the rebuilding of cartilage. One dosage of the composition contains approximately 30 mg of collagen.
salacin. One dosage of the composition contains approximately 50 mg of white willow bark.
Yucca root powder acts as an anti-inflammatory agent in the composition. It is derived from Yucca schidigera. One dosage of the composition contains approximately 15 mg of yucca root powder.
Devil's claw acts as an anti-inflammatory agent in the composition.
It is derived from Harpagophytum procumbens. One dosage of the composition contains approximately 15 mg of devil's claw.
Sarsaparilla acts as an anti-inflammatory agent in the composition.
It is derived from Smilax sp. One dosage of the composition contains approximately 15 mg of sarsaparilla.
Feverfew leaf powder acts as a pain reliever in the composition. It is derived from Tanacetum parthenium. One dosage of the composition contains approximately 10 mg of feverfew leaf powder.
Bromelain acts as an anti-inflammatory agent in the composition.
One dosage of the composition contains approximately 5 mg.
The collagen used in the composition is preferably Type II collagen.
The unhydrolyzed form is preferred for ready absorption into the body tissues. Collagen promotes the rebuilding of cartilage. One dosage of the composition contains approximately 30 mg of collagen.
Pantothenic acid is a component of the composition and promotes tissue formation. One dosage of the composition contains approximately 5 mg.
The preferred minerals in the composition are copper, manganese and selenium. Copper helps produce red blood cells and connective tissue.
One dosage of the composition contains approximately 350 mcg of copper.
Manganese is a component that acts in the process of bone metabolism. One dosage of the composition contains approximately 750 mcg of manganese.
Selenium is a non-metallic mineral component of the composition that is a factor in the maintenance of health body cells and tissues. One dosage of the composition contains approximately 13 mcg of selenium.
The composition of invention is made by the following method. A
mixture of the glucosamine sulphate, the collagen and the plant materials or extracts, all of which are in dry powdered form, is prepared. A second mixture is prepared comprising the pantothenic acid and the copper, manganese and selenium. These two mixtures are mixed together and the resulting powdered mixture is used to prepare single-dosage capsules.
Alternatively, the composition and/or the second mixture (the pantothenic acid, copper, manganese and selenium) can be used by topical administration.
Example 1 A pharmaceutical preparation is compounded as a dry powdered mix and is made into single-dosage capsules. The ingredients, their weight percent in the total composition and their weights in a single capsule are as shown in Table 1.
Ingredient Weight Percent Weight in Single Capsule Pantothenic acid 0.907 5 mg Copper 0.0635 350 mcg Manganese 0.136 750 mcg Selenium 0.0235 13 mcg Glucosamine sulphate 68.0 375 mcg Boswellia extract 10.9 60 mg Collagen 0.0054 30 mg White willow bark 9.07 50 mg Yucca root powder 2.73 15 mg Devil's claw 2.73 15 mg Sarsaparilla 2.73 15 mg Feverfew leaf powder 1.81 10 mg Bromelain 0.907 5 mg The capsules are administered to an adult human at a rate of 4 to 6 capsules per day until the arthritic symptoms are relieved. They are then administered at a maintenance dosage of 2 to 4 capsules per day.
Although the invention has been described in terms of specific embodiments, it is not intended that the invention be limited to those embodiments. Various modifications of the invention will be apparent to those skilled in the art. The scope of the invention is defined by the claims that follow.
The preferred minerals in the composition are copper, manganese and selenium. Copper helps produce red blood cells and connective tissue.
One dosage of the composition contains approximately 350 mcg of copper.
Manganese is a component that acts in the process of bone metabolism. One dosage of the composition contains approximately 750 mcg of manganese.
Selenium is a non-metallic mineral component of the composition that is a factor in the maintenance of health body cells and tissues. One dosage of the composition contains approximately 13 mcg of selenium.
The composition of invention is made by the following method. A
mixture of the glucosamine sulphate, the collagen and the plant materials or extracts, all of which are in dry powdered form, is prepared. A second mixture is prepared comprising the pantothenic acid and the copper, manganese and selenium. These two mixtures are mixed together and the resulting powdered mixture is used to prepare single-dosage capsules.
Alternatively, the composition and/or the second mixture (the pantothenic acid, copper, manganese and selenium) can be used by topical administration.
Example 1 A pharmaceutical preparation is compounded as a dry powdered mix and is made into single-dosage capsules. The ingredients, their weight percent in the total composition and their weights in a single capsule are as shown in Table 1.
Ingredient Weight Percent Weight in Single Capsule Pantothenic acid 0.907 5 mg Copper 0.0635 350 mcg Manganese 0.136 750 mcg Selenium 0.0235 13 mcg Glucosamine sulphate 68.0 375 mcg Boswellia extract 10.9 60 mg Collagen 0.0054 30 mg White willow bark 9.07 50 mg Yucca root powder 2.73 15 mg Devil's claw 2.73 15 mg Sarsaparilla 2.73 15 mg Feverfew leaf powder 1.81 10 mg Bromelain 0.907 5 mg The capsules are administered to an adult human at a rate of 4 to 6 capsules per day until the arthritic symptoms are relieved. They are then administered at a maintenance dosage of 2 to 4 capsules per day.
Although the invention has been described in terms of specific embodiments, it is not intended that the invention be limited to those embodiments. Various modifications of the invention will be apparent to those skilled in the art. The scope of the invention is defined by the claims that follow.
Claims (9)
1. A pharmaceutical composition for treating arthritis, comprising:
(a) glucosamine or a salt thereof;
(b) plant materials or extracts;
(c) collagen;
(d) pantothenic acid; and (e) minerals.
(a) glucosamine or a salt thereof;
(b) plant materials or extracts;
(c) collagen;
(d) pantothenic acid; and (e) minerals.
2. A composition according to claim 1 wherein said minerals comprise copper, manganese and selenium.
3. A composition according to claim 1 or 2 wherein said glucosamine salt is glucosamine sulphate.
4. A composition according to any one of claims 1 - 3 wherein said plant materials or extracts comprise boswellia extract, white root bark, yucca root powder, devil's claw, sarsaparilla, feverfew leaf powder and bromelain.
5. A composition according to any one of claims 1 - 4 wherein said collagen is Type II collagen.
6. A composition according to any one of claims 1 - 5 wherein said composition is in a form for oral administration.
7. A composition according to claim 6 wherein one dosage of said composition for oral administration comprises at least 375 mg of said glucosamine salt, at least 5 mg of pantothenic acid, at least 35 mg of copper, at least 750 mg of manganese and at least 13 mcg of selenium.
8. A composition according to claim 6 or 7 wherein each of said components is present in a medicinally-effective amount.
9. A composition according to any one of claims 1 - 7 wherein said pantothenic acid, copper, manganese and selenium are present at a level totaling at least 1% by weight of said pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002559634A CA2559634A1 (en) | 2006-09-13 | 2006-09-13 | Pharmaceutical preparations for the treatment of arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002559634A CA2559634A1 (en) | 2006-09-13 | 2006-09-13 | Pharmaceutical preparations for the treatment of arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2559634A1 true CA2559634A1 (en) | 2008-03-13 |
Family
ID=39181984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002559634A Abandoned CA2559634A1 (en) | 2006-09-13 | 2006-09-13 | Pharmaceutical preparations for the treatment of arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2559634A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015067563A (en) * | 2013-09-27 | 2015-04-13 | 小林製薬株式会社 | Oral composition |
| CN108143977A (en) * | 2016-12-02 | 2018-06-12 | 蒋荣华 | A kind of multi-function health-care medicinal liquor |
-
2006
- 2006-09-13 CA CA002559634A patent/CA2559634A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015067563A (en) * | 2013-09-27 | 2015-04-13 | 小林製薬株式会社 | Oral composition |
| CN108143977A (en) * | 2016-12-02 | 2018-06-12 | 蒋荣华 | A kind of multi-function health-care medicinal liquor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5888514A (en) | Natural composition for treating bone or joint inflammation | |
| JP5662492B2 (en) | Anti-inflammatory preparation | |
| Elghandour et al. | Plant bioactives and extracts as feed additives in horse nutrition | |
| US6793942B2 (en) | Composition and method for treating the effects of diseases and maladies | |
| US7282224B1 (en) | Pain relief composition | |
| US6841544B2 (en) | Composition and method for treating the effects of diseases and maladies | |
| US6787164B2 (en) | Composition and method for treating the effects of diseases and maladies | |
| US20020128273A1 (en) | Composition and method for treating the effects of diseases and maladies | |
| US6759062B2 (en) | Composition and method for treating the effects of diseases and maladies | |
| US20210145945A1 (en) | Radioprotection, Radiomitigation and Radiorecovery | |
| US20230346869A1 (en) | Formulation for management of post-oral surgical recovery and maintenance of oral health | |
| EP1185281A1 (en) | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe | |
| US20040086581A1 (en) | Bio-energetic joint and arthritis pain formula | |
| CA2559634A1 (en) | Pharmaceutical preparations for the treatment of arthritis | |
| US20030125303A1 (en) | Transdermal formulation for repair and maintenance of connective tissue | |
| US20020034555A1 (en) | Composition and method for treating the effects of diseases and maladies | |
| Khan et al. | Immunopotentiating effect of Khamira Marwarid, an herbo-mineral preparation. | |
| JP2001346545A (en) | Dietary supplement | |
| JP2001524080A (en) | Composition comprising hydrolyzed collagen protein and glucosamine for the treatment of arthritis | |
| ES2822660T3 (en) | Preparation for the treatment of arthritis and osteoarthritis | |
| US20010043959A1 (en) | Composition and method for treating the effects of diseases and maladies | |
| Verma et al. | Rheumatoid arthritis therapeutics: The neoteric approaches | |
| CN106177269A (en) | The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application | |
| RU2104026C1 (en) | Curative-prophylactic agent showing tonic and total restorative action | |
| Wynn | Ten herbs and nutraceuticals you can't live without. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |